Fluspirilene (Imap) in the treatment of psychosomatic complaints in hypochondriacal patients.
Patients with psychosomatic complaints of a hypochondriacal nature were treated with a weekly IM dose of 1.2-1.5 mg fluspirilene (0.6-0.75 ml IMAP) for a period of 10 weeks. According to the physicians' ratings, good results were obtained in 58%, moderate ones in 28%. In the patients' ratings, this corresponded to 60 and 26% respectively. Acceptability of the treatment was assessed as good by 88% of the physicians and 90% of the patients. Only two side effects were reported by three patients alike (dry mouth and sweating). The other side-effects were rarer in occurrence and half of them were transient.
D000293:Adolescent; D000328:Adult; D000368:Aged; D017109:Akathisia, Drug-Induced; D001835:Body Weight; D003863:Depression / Q000139:chemically induced; D005260:Female; D005484:Fluspirilene / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006945:Hyperhidrosis / Q000139:chemically induced; D006998:Hypochondriasis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012894:Sleep Stages; D013001:Somatoform Disorders / Q000188:drug therapy*; D013141:Spiro Compounds / Q000627:therapeutic use*; D014987:Xerostomia / Q000139:chemically induced
D013141:Spiro Compounds; D005484:Fluspirilene